Department of Pathology, Stanford University Hospital, Room L235, 300 Pasteur Drive, Stanford, CA 94305, USA.
Breast Cancer Res Treat. 2010 Sep;123(2):397-404. doi: 10.1007/s10549-009-0654-0. Epub 2009 Dec 1.
Recent advances in the study of the tumor microenvironment have revealed significant interaction between tumor cells and their surrounding stroma in model systems. We have previously shown that two distinct stromal signatures derived from a macrophage (CSF1) response and a fibroblastic (DTF-like) response are present in subsets of invasive breast cancers and show a correlation with clinical outcome. In the present study we explore whether these signatures also exist in the stroma of ductal carcinoma in situ (DCIS). We studied the signatures by both gene expression profile analysis of a publically available data set of DCIS and by immunohistochemistry (IHC) on a tissue microarray of DCIS and invasive breast cancer cases. Both the gene expression and immunohistochemical data show that the macrophage response and fibroblast expression signatures are present in the stroma of subsets of DCIS cases. The incidence of the stromal signatures in DCIS is similar to the incidence in invasive breast cancer that we have previously reported. We also find that the macrophage response signature is associated with higher grade DCIS and cases which are ER and PR negative, whereas the fibroblast signature was not associated with any clinicopathologic features in DCIS. A comparison of 115 matched cases of DCIS and invasive breast cancer found a correlation between the type of stromal response in DCIS and invasive ductal carcinoma (IDC) within the same patient for both the macrophage response and the fibroblast stromal signatures (P = 0.03 and 0.08, respectively). This study is a first characterization of these signatures in DCIS. These signatures have significant clinicopathologic associations and tend to be conserved as the tumor progresses from DCIS to invasive breast cancer.
近年来,对肿瘤微环境的研究进展揭示了模型系统中肿瘤细胞与其周围基质之间的显著相互作用。我们之前已经表明,两种不同的基质特征,即源自巨噬细胞(CSF1)反应的特征和源自成纤维细胞(DTF 样)反应的特征,存在于浸润性乳腺癌的亚群中,并与临床结果相关。在本研究中,我们探讨了这些特征是否也存在于导管原位癌(DCIS)的基质中。我们通过公共 DCIS 数据集的基因表达谱分析和 DCIS 和浸润性乳腺癌病例的组织微阵列免疫组织化学(IHC)来研究这些特征。基因表达和免疫组织化学数据均表明,巨噬细胞反应和成纤维细胞表达特征存在于亚组 DCIS 病例的基质中。DCIS 中基质特征的发生率与我们之前报道的浸润性乳腺癌的发生率相似。我们还发现,巨噬细胞反应特征与高级别 DCIS 和 ER 和 PR 阴性病例相关,而成纤维细胞特征与 DCIS 中的任何临床病理特征均无关。对 115 对匹配的 DCIS 和浸润性乳腺癌病例的比较发现,在同一患者中,DCIS 和浸润性导管癌(IDC)中的基质反应类型与巨噬细胞反应和成纤维细胞基质特征之间存在相关性(分别为 P = 0.03 和 0.08)。本研究首次对这些特征在 DCIS 中的特征进行了描述。这些特征具有显著的临床病理相关性,并倾向于在肿瘤从 DCIS 进展为浸润性乳腺癌时保持保守。